Small-cell lung cancer, limited stage research hub

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

This phase 3 trial looks at whether an immunotherapy drug called durvalumab helps people with limited-stage small cell lung cancer live longer. It tests if giving durvalumab through a drip after standard chemotherapy and radiotherapy helps keep the cancer from returning.